



We want to save patients with severe cancer and autoimmune diseases
Clinical investigations with our lead antibody CAN04 to our proprietary target

Göran Forsberg, CEO

Safe Harbour Statement

The following presentation may include predictions, estimates or other information that might be considered forward-looking. The statements regarding the surrounding world and future circumstances in this presentation reflect Cantargia's current thinking with respect to future events and financial performance. Prospective statements only express the assessments and assumptions the company makes at the time of the presentation. These statements are well-considered, but the audience should note that, as with all prospective assessments, they are associated with risks and uncertainties.

Directed share issue of 106 MSEK



Press release

Cantargia AB
556791-6019
2019-03-21

Cantargia makes a directed share issue of approximately SEK 106 million for increased investments in the clinical development of CAN04

The board of directors of Cantargia AB (publ) has resolved, pursuant to the general meeting's authorization, on a directed share issue of approximately SEK 106 million. The proceeds from the share issue enable expanded investments in the company's main project, CAN04 (nidanimab), with a new clinical study in the US and an expansion of the most promising patient sub-group of the ongoing clinical CANFOUR study. CAN04 is an antibody in phase IIa clinical development against non-small cell lung cancer and pancreatic cancer.

In the directed share issue, 6,618,581 new shares are issued at a subscription price of approximately SEK 16.02 per share, which means that the company is provided with approximately SEK 106 million in issue proceeds, before issue costs. The subscription price corresponds to the volume weighted average price of the Cantargia share during the latest 20 trading days.


The investors are a number of Nordic institutional investors; Alecta (approximately SEK 76.5 million), Handelsbanken Fonder (SEK 7.6 million), EWS Foundation (SEK 3.8 million) and Jesem AS (SEK 1.8 million). In addition thereto a number of private investors have subscribed for shares for approximately SEK 16.2 million, through Avanza Pension.

"Market price" (16.02 SEK)


- **Alecta 76.5 MSEK**
- **Handelsbanken fonder 7.6 MSEK**
- **EWS Foundation 3.MSEK**
- **Jesem AS 1.8 MSEK**
- **Private investors 16.2 MSEK**

Cantargia – opportunity to save lives and create value

- Potentially more effective treatment against novel target in clinically validated pathway
- Right team and clear plan to position our projects and maximize value
- First in class platform technology against novel target



Cantargia core – tumor inflammation



Cancer caused by two enablers:


- Genomic instability/mutations
- Inflammation

Counteracting inflammation - strategy for novel therapies

Validating study – counteracting tumor inflammation

CANTOS trial (n=10061)

- Canakinumab (Novartis)
- Reduced lung cancer incidence by 67 % and death by 77 %.



- Clinical validation of IL-1 pathway
- Dose/response
- Cantargia's CAN04 has broader MOA



Novartis has started:

3 phase 3 trials in non-small cell lung cancer

.....And clinical development in:

- **Renal cell cancer**
- **Gastresophageal cancer**
- **Colorectal cancer**

CAN04 (nidanilimab) added value vs canakinumab




Canakinumab

- Antibody directed against one of the two IL-1 ligands, IL-1 β

CAN04:

Double mechanism

- Binds the signaling receptor and counteracts both ligands
- Induce killing via the immune system (ADCC)




CAN04 has a strong potential to treat cancer

CAN04 – CANFOUR clinical trial

Phase I/IIa trial - NSCLC and pancreatic cancer


- Jules Bordet, Brussels; Erasmus Rotterdam, NKI, Amsterdam; Rigshospitalet, Copenhagen; Radiumhospitalet, Oslo
- 22 patients treated:
 - Good safety up to 10 mg/kg
 - Significant effect on relevant biomarkers (IL-6, CRP)
 - 5/13 pts had stable disease up to 6 months
 - NSCLC, pancreatic cancer, colon cancer
- Phase IIa: focused on NSCLC and pancreatic cancer (appr 20 centres)
 - FPI Jan 2019 –Data early 2020
 - Monotherapy (appr 20 pat)
 - Combination with standard therapy (appr 30 pat per arm)
 - NSCLC Cisplatin/Gemcitabine
 - Pancreatic cancer Gemcitabine/nab-paclitaxel



Details on www.clinicaltrials.gov

Generation of data instrumental for next phase of development

CAN04 – CANFOUR clinical trial and next steps



CANFOUR can be advanced to next value inflection point

Two major preclinical findings during 2018

-new opportunities

Binding to immune cells in tumor microenvironment

- Antimetastatic effects
- Counteract immune suppression

Synergistic effects with chemotherapy

- Stronger antitumor effects
- Counteracts chemotherapy toxicity

Significant value inflection points ahead of CANFOUR results

2019

- US strategy and new clinical trial
- Clinical progress and initial phase IIa results
- Preclinical progress (immuno-oncology effects, combinations etc)
- CANxx progress

2020

- Phase IIa results
- Phase IIa expansion in most promising subgroup

Significant data to secure newsflow 2019-2020

Cantargia

- Specialized in antibody therapy/immunology - initial focus on oncology
- Lead antibody CAN04 (nidanilimab) in phase IIa clinical development, pathway clinically validated, data early 2020
- Platform around IL1RAP, lead candidate for autoimmunity and inflammatory disease 2019
- Granted IP - therapeutic target IL1RAP and CAN04
- Strong management team with proven track record in clinical development and business development
- Listed on Nasdaq Stockholm
- Approximately 5000 shareholders incl strong long term investors
- Based in Lund, Sweden

Financial highlights

- Share price: 18.00 SEK (1.95 USD), Mar 27, 2019
- Market cap: 1191 MSEK (129 MUSD), Mar 27, 2019
- Cash: 167 MSEK (18.1 MUSD), Dec 31, 2018 + 106 MSEK from directed share issues

Current owners (Dec 31, 2018)

Sunstone	9.0%
1st AP fund	6.9%
SEB S.A.	5.0%
Avanza Pension	5.0%
4th AP fund	4.6%
Öhman Bank S.A.	4.1%
2nd AP fund	3.3%
Mats Invest AB	2.0%
Tibia konsult	1.9%
Kudu AB	1.9 %
Others	56.3%